Ion Exchange (India) Limited has submitted its investor presentation for the financial year ending March 31, 2027 (FY27), to the Bombay Stock Exchange and the National Stock Exchange of India Limited on August 10, 2026. The filing, made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, outlines the company’s strategic roadmap, including a restructuring of its financial reporting segments and major capacity expansion initiatives across its manufacturing footprint.

The company announced a transition from its existing three-segment reporting structure—Engineering, Chemicals, and Consumer Products—to a more granular five-segment model. This change aims to provide greater clarity on revenue streams and operational performance. The new segments are Treatment Solutions, Industrial Products, Lifecycle Services, Specialty Chemicals, and Consumer Products. This restructuring reflects the company’s evolving business mix, which now places significant emphasis on services and specialty chemical offerings alongside traditional engineering and consumer goods.

Strategic Capacity Expansions

The presentation details aggressive scaling plans in core manufacturing areas to strengthen global competitiveness. Key investments include:

In Ankleshwar, Gujarat, the company is expanding conventional resin capacity and has established India’s first Non-Solvent Resin manufacturing facility. Additionally, an Integrated Spent Acid Recovery system has been implemented to enable circular manufacturing, described as a global first. For pharma resins, the expansion includes enhanced FDA-approved manufacturing capacity and the introduction of new Weak Acid Cation and Acrylic Anion resin grades.

Global Manufacturing and R&D Footprint

Ion Exchange continues to leverage its six-decade legacy in water treatment technology, supported by over 50 patents and 100+ products launched since its founding in 1965. The company operates multiple Centers of Excellence, including a Technology Centre in Vashi, Maharashtra, and a Chemical Centre in Patancheru, Telangana. These facilities focus on systems design, application testing, resin development, and microbiology research.

The company’s global manufacturing network spans India, Saudi Arabia, Portugal, UAE, South Africa, Indonesia, and Bangladesh. In Goa, the Verna facility serves as a Centre of Membrane Excellence, supporting the production of Reverse Osmosis (RO), Ultrafiltration (UF), Nanofiltration (NF), and Membrane Bioreactor (MBR) systems. The UAE assembly unit is ICV certified, reinforcing the company’s presence in the Middle East.

Emerging Solutions and Digital Integration

The FY27 presentation highlights growth in emerging solution categories, including Brine Valuation, Lithium Extraction, New Energy Solutions, Semiconductor Solutions, Data Center Solutions, and Digital Solutions. Specific initiatives include:

• Lithium Extraction: Recovering lithium from battery waste and brines using advanced membrane and resin solutions.
• Semiconductors & Data Centers: Providing Ultra Pure Water (UPW) systems and condensate polishing for high-purity requirements.
• Digital Assets: Deploying AI-Powered IonSiTE Remote Asset Performance Management (APM) and Digital Twins for oil & gas, utilities, infrastructure, and data centers.

Consumer and Services Growth

In the consumer segment, the ZeroB brand aims to expand its alkaline and hydrogen water portfolio while improving margins through product optimization. The company plans to scale adjacent categories such as On-The-Go (OTG) purifiers, heat pumps, and pressure pumps. ZeroB currently serves more than 4 Lacs customers through a nationwide service network covering 700+ cities with 2,000+ trained engineers.

The Lifecycle Services division, established as India’s most comprehensive platform for water and wastewater treatment, offers Operations & Maintenance (O&M), rehabilitation, spares, BOO/BOOT/WaaS models, and remote monitoring. The division holds ISO certification and operates NABL and RBNQ certified laboratories.

What the Numbers Show

The shift to five reporting segments signals a strategic pivot towards higher-margin services and specialty chemicals, rather than relying solely on capital-intensive engineering projects. By explicitly separating Specialty Chemicals and Lifecycle Services, Ion Exchange is highlighting recurring revenue streams and high-value niche products. The ambitious target of increasing pharma resin market share from 3.5% to 17% suggests a strong belief in the domestic pharma sector’s growth and the company’s ability to capture larger volumes through localized, FDA-compliant manufacturing.

Ion Exchange (India) Limited reported a significant contraction in profitability for the first quarter of FY26, with standalone net profit after tax (PAT) falling 75.7% year-on-year to ₹11.40 crore. The company's consolidated PAT dropped sharply to ₹3.06 crore, compared to ₹48.44 crore in Q1FY25, reflecting severe margin pressure and higher operational costs. The results were approved by the Board of Directors on August 5, 2026.

Key Financial Metrics

The latest quarterly results reveal a stark divergence between revenue growth and profitability. While consolidated revenue from operations rose 20.1% year-on-year to ₹700.46 crore, earnings metrics deteriorated sharply across the board. The following table summarises the key consolidated performance indicators:

The EBITDA contraction to ₹31.70 crore from ₹62.50 crore underscores the depth of margin erosion during the quarter. The EBITDA margin nearly halved to 4.53% from 10.72% in Q1FY25, pointing to a significant rise in operating costs relative to revenue. Finance costs rose substantially to ₹8.21 crore on a standalone basis from ₹1.66 crore in Q1FY25, while consolidated finance costs more than tripled to ₹8.95 crore from ₹2.56 crore, further weighing on the bottom line. Other income also decreased to ₹13.24 crore from ₹19.52 crore, with total standalone income reaching ₹64.88 crore. The decline in standalone profit before tax and exceptional items to ₹15.37 crore from ₹63.04 crore in Q1FY25 further reflects the operational challenges faced during the quarter.

Segment Performance

The company realigned its segment reporting structure effective April 1, 2026, renaming its Engineering segment into Treatment Solutions, Industrial Products, and Lifecycle Services. The table below presents the standalone segment-wise revenue and results:

Treatment Solutions emerged as the largest revenue contributor at ₹201.00 crore but reported a loss of ₹18.26 crore, reversing a profit of ₹18.34 crore in Q1FY25. Specialty Chemicals remained the most profitable segment with a result of ₹24.76 crore, though down from ₹41.11 crore in the prior year. Industrial Products saw revenue growth to ₹105.53 crore from ₹88.45 crore, with results improving to ₹13.66 crore from ₹4.64 crore.

Regulatory and Legal Updates

The auditor's report included an Emphasis of Matter regarding subsidiary Ion Exchange Enviro Farms Limited (IEEFL). SEBI had directed IEEFL to deposit ₹22.02 crore towards investor repayment following a forensic audit. IEEFL has appealed this order before the Securities Appellate Tribunal (SAT), where the next hearing is scheduled for August 12, 2026. During the October 2024 hearing, SEBI's counsel stated that no recovery proceedings would be initiated until the next hearing date. The company does not envisage any liability on this account pending the final outcome.

Deloitte Haskins & Sells LLP reviewed the interim financial statements, confirming compliance with Ind AS 34 and SEBI Listing Regulations. The results include unreviewed financial information from certain subsidiaries and associates, which management deemed immaterial to the group's overall performance.